Commercial

Medfusion Announces Enhancements to Mobile Patient App

February 22, 2017

CARY, N.C.–(BUSINESS WIRE)–(HIMSS17 #MP36) – Medfusion, a leading provider of patient experience solutions, today announced enhancements to Medfusion Plus, the free mobile app that gives patients one place to securely view all health data for themselves and all family members. “We’ve ensured patients can quickly and easily share information with providers, added additional facilities to […]

Graft Versus Host Disease (GVHD) Epidemiology Insights, 2013-2023 – Research and Markets

February 22, 2017

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Graft Versus Host Disease (GVHD) – Epidemiology Insights – 2023” report to their offering. “Graft Versus Host Disease (GVHD) – Epidemiology Insights – 2023” Tweet this This report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident […]

Recurrent Glioblastoma Multiforme (GBM) – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017-2018 – Research and Markets

February 22, 2017

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Recurrent Glioblastoma Multiforme (GBM) – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017” drug pipelines to their offering.   “Recurrent Glioblastoma Multiforme (GBM) – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017” Tweet this Recurrent Glioblastoma Multiforme – Global API Manufacturers, […]

Repatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option

February 22, 2017

THOUSAND OAKS, Calif., Feb. 21, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has adopted a decision to change the Repatha® (evolocumab) marketing authorization, approving a new single-dose delivery option. The new automated mini-doser (AMD) with a pre-filled cartridge is a hands-free device that provides 420 mg of Repatha in a […]

Tauopathy drugs for neurodegenerative diseases could take off after first-to-market drug is launched, says GlobalData

February 22, 2017

The tauopathies market, which covers more than 20 neurodegenerative diseases such as progressive supranuclear palsy and corticobasal degeneration characterized by tau protein aggregation in the brain, will be driven primarily by the development of novel therapeutics with a first-to-market drug boosting sales and encouraging pharma companies to focus R&D efforts on this market, according to […]

Beyond the Moustache: PatientPoint Takes The Movember Foundation to Point of Care

February 22, 2017

CINCINNATI – (February 16, 2017) – Movember Foundation, the only global charity solely focused on men’s health, will expand their audience of Mo Bros and Mo Sistas through PatientPoint®. PatientPoint®, the trusted leader in patient education and engagement at the point of care, will now feature men’s health messaging about the Foundation’s funded programs in […]

Certara Strategic Consulting Awarded Good Laboratory Practices (GLP) Compliant Toxicokinetic Test Site Certification

February 22, 2017

CSC’s pre-clinical toxicology and pharmacokinetics modeling and simulation are used to inform first-in-human dosing in Phase 1 trials Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that the Standards Council of Canada (SCC) has awarded Good Laboratory Practices (GLP) certification to its […]

Aytu BioScience Announces Expansion of U.S. Sales Team to Support Increasing Growth of Natesto Prescriptions and Revenues

February 22, 2017

ENGLEWOOD, Colo., Feb. 22, 2017 /PRNewswire/ — Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the expansion of its U.S. sales team to up to 42 account managers from 35 currently, a 20% increase in the company’s commercial footprint. The […]

SAPHEX 2017

February 21, 2017

Rockwell Medical Updates Progress on Calcitriol Commercial Launch

February 21, 2017

WIXOM, Mich., Feb. 21, 2017 (GLOBE NEWSWIRE) — Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today provided an update on the commercial launch progress of Calcitriol, stating that the FDA has […]

Global Graft Versus Host Disease (GVHD) Market 2017-2027

February 21, 2017

LONDON, February 20, 2017 /PRNewswire/ — Acute, Chronic and Prophylaxis GVHD The global graft versus host disease market is expected to grow at a CAGR of 7% from 2016-2021 and CAGR of 3% from 2021-2027. The market is expected to grow at a CAGR of 6% from 2016 to 2027. The market is estimated at […]

Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients

February 21, 2017

LAVAL, Quebec and WALTHAM, Mass., Feb. 21, 2017 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) and EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG) (“EyeGate”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that they have entered into an exclusive, […]

QPharma Expands Client Base with Innovative KOL Influence Mapping Solution

February 20, 2017

MORRISTOWN, N.J.–(BUSINESS WIRE)–QPharma, a premier provider of compliance and commercial services to the life sciences industry, is expanding its client base for Key Opinion Leader (KOL) solutions. Recently, the firm was contracted by a top-25 pharmaceutical manufacturer for a seven-figure KOL influence mapping project. QPharma expands client base with innovative KOL influence mapping solution. Tweet […]

ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials

February 20, 2017

DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US Food & Drug Administration (FDA) to validate three Patient Reported Outcomes (PRO) instruments that will measure clinical endpoints in antibacterial drug […]

FEEDBACK